Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 510105, 13 pages
http://dx.doi.org/10.1155/2015/510105
Review Article

Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea

Section of Pulmonary & Critical Care, Department of Medicine, University of Chicago, Chicago, IL 60637, USA

Received 2 February 2015; Accepted 17 March 2015

Academic Editor: Nina Ivanovska

Copyright © 2015 Ayodeji Adegunsoye and Jay Balachandran. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. G. Luzina, N. W. Todd, S. Sundararajan, and S. P. Atamas, “The cytokines of pulmonary fibrosis: much learned, much more to learn,” Cytokine, 2014. View at Publisher · View at Google Scholar
  2. A. U. Wells, “The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)—practical implications,” Respiratory Research, vol. 14, supplement 1, article S2, 2013. View at Google Scholar
  3. N. Ahluwalia, B. S. Shea, and A. M. Tager, “New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 8, pp. 867–878, 2014. View at Publisher · View at Google Scholar
  4. J. P. Hutchinson, T. M. McKeever, A. W. Fogarty, V. Navaratnam, and R. B. Hubbard, “Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century,” Annals of the American Thoracic Society, vol. 11, no. 8, pp. 1176–1185, 2014. View at Publisher · View at Google Scholar
  5. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2083–2092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Richeldi, R. M. du Bois, G. Raghu et al., “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Selman and A. Pardo, “Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis: an integral model,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 10, pp. 1161–1172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. L. H. Lancaster, W. R. Mason, J. A. Parnell et al., “Obstructive sleep apnea is common in idiopathic pulmonary fibrosis,” Chest, vol. 136, no. 3, pp. 772–778, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. J. Epstein, D. Kristo, P. J. Strollo Jr. et al., “Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults,” Journal of Clinical Sleep Medicine, vol. 5, no. 3, pp. 263–276, 2009. View at Google Scholar · View at Scopus
  10. C. Mermigkis, E. Stagaki, S. Tryfon et al., “How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis?” Sleep and Breathing, vol. 14, no. 4, pp. 387–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Pihtili, Z. Bingol, E. Kiyan, C. Cuhadaroglu, H. Issever, and Z. Gulbaran, “Obstructive sleep apnea is common in patients with interstitial lung disease,” Sleep and Breathing, vol. 17, no. 4, pp. 1281–1288, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Mermigkis, I. Bouloukaki, K. Antoniou et al., “Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis,” Sleep Breath, vol. 19, no. 1, pp. 385–391, 2014. View at Publisher · View at Google Scholar
  13. P. Lévy, J.-L. Pépin, C. Arnaud et al., “Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives,” European Respiratory Journal, vol. 32, no. 4, pp. 1082–1095, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Neubauer, “Invited review: physiological and pathophysiological responses to intermittent hypoxia,” Journal of Applied Physiology, vol. 90, no. 4, pp. 1593–1599, 2001. View at Google Scholar · View at Scopus
  15. L. Kolilekas, E. Manali, K. A. Vlami et al., “Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis,” Journal of Clinical Sleep Medicine, vol. 9, no. 6, pp. 593–601, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. T. J. Huie, A. L. Olson, G. P. Cosgrove et al., “A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes,” Respirology, vol. 15, no. 6, pp. 909–917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. L. Olson, T. J. Huie, S. D. Groshong et al., “Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series,” Chest, vol. 134, no. 4, pp. 844–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Adegunsoye and S. Ramachandran, “Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders,” Pulmonary Medicine, vol. 2012, Article ID 273591, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Casali, P. Carratù, and M. Sofia, “Clinical variability of respiratory pulmonary hypertension: implications for diagnosis and management,” Multidisciplinary Respiratory Medicine, vol. 8, article 72, 2013. View at Publisher · View at Google Scholar
  20. T. Kiss, K. Kovacs, A. Komocsi et al., “Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt,” PLoS ONE, vol. 9, no. 8, Article ID e104890, 2014. View at Publisher · View at Google Scholar
  21. R. Wolk and V. K. Somers, “Obesity-related cardiovascular disease: implications of obstructive sleep apnea,” Diabetes, Obesity and Metabolism, vol. 8, no. 3, pp. 250–260, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. B. G. Phillips, M. Kato, K. Narkiewicz, I. Choe, and V. K. Somers, “Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 279, no. 1, pp. H234–H237, 2000. View at Google Scholar · View at Scopus
  23. K. Chin, K. Shimizu, T. Nakamura et al., “Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy,” Circulation, vol. 100, no. 7, pp. 706–712, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Sun, N. Halberg, M. Khan, U. J. Magalang, and P. E. Scherer, “Selective inhibition of Hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction,” Molecular and Cellular Biology, vol. 33, no. 5, pp. 904–917, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Pillai, A. L. Olson, T. J. Huie et al., “Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease,” Respiratory Medicine, vol. 106, no. 7, pp. 1033–1039, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. E. L. Vukovac, M. Lozo, K. Mise et al., “Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: a case-control study,” Medical Science Monitor, vol. 20, pp. 255–261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. K. A. Smith, G. Voiriot, H. Tang et al., “Notch activation of Ca2+ signaling mediates hypoxic pulmonary vasoconstriction and pulmonary hypertension,” American Journal of Respiratory Cell and Molecular Biology, 2015. View at Publisher · View at Google Scholar
  28. B. M. Tsai, M. Wang, J. M. Pitcher, K. K. Meldrum, and D. R. Meldrum, “Hypoxic pulmonary vasoconstriction and pulmonary artery tissue cytokine expression are mediated by protein kinase C,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 287, no. 6, pp. L1215–L1219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. H.-W. Duchna, “Sleep-related breathing disorders—a second edition of the International Classification of Sleep Disorders (ICSD-2) of the American Academy of Sleep Medicine (AASM),” Pneumologie, vol. 60, no. 9, pp. 568–575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Sateia, “International classification of sleep disorders-third edition: highlights and modifications,” CHEST Journal, vol. 146, no. 5, pp. 1387–1394, 2014. View at Publisher · View at Google Scholar
  31. K. Rasche and M. Orth, “Sleep and breathing in idiopathic pulmonary fibrosis,” Journal of Physiology and Pharmacology, vol. 60, supplement 5, pp. 13–14, 2009. View at Google Scholar · View at Scopus
  32. R. Perez-Padilla, P. West, M. Lertzman, and M. H. Kryger, “Breathing during sleep in patients with interstitial lung disease,” American Review of Respiratory Disease, vol. 132, no. 2, pp. 224–229, 1985. View at Google Scholar · View at Scopus
  33. P. T. P. Bye, F. Issa, M. Berthon-Jones, and C. E. Sullivan, “Studies of oxygenation during sleep in patients with interstitial lung disease,” American Review of Respiratory Disease, vol. 129, no. 1, pp. 27–32, 1984. View at Google Scholar · View at Scopus
  34. C. Mermigkis, J. Chapman, J. Golish et al., “Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis,” Lung, vol. 185, no. 3, pp. 173–178, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Aydogdu, B. Ciftci, S. Firat Guven, T. Ulukavak Ciftci, and Y. Erdogan, “Assessment of sleep with polysomnography in patients with interstitial lung disease,” Tuberkuloz ve Toraks, vol. 54, no. 3, pp. 213–221, 2006. View at Google Scholar · View at Scopus
  36. M. Clark, B. Cooper, S. Singh, M. Cooper, A. Carr, and R. Hubbard, “A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis,” Thorax, vol. 56, no. 6, pp. 482–486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Series, Y. Cormier, N. Lampron, and J. La Forge, “Increasing the functional residual capacity may reverse obstructive sleep apnea,” Sleep, vol. 11, no. 4, pp. 349–353, 1988. View at Google Scholar · View at Scopus
  38. R. C. Heinzer, M. L. Stanchina, A. Malhotra et al., “Lung volume and continuous positive airway pressure requirements in obstructive sleep apnea,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 1, pp. 114–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. L. Shepherd, R. H. Holloway, D. R. Hillman, and P. R. Eastwood, “The impact of continuous positive airway pressure on the lower esophageal sphincter,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 292, no. 5, pp. G1200–G1205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. F. H. Kuniyoshi, A. Garcia-Touchard, A. S. Gami et al., “Day-night variation of acute myocardial infarction in obstructive sleep apnea,” Journal of the American College of Cardiology, vol. 52, no. 5, pp. 343–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. M. Parish and V. K. Somers, “Obstructive sleep apnea and cardiovascular disease,” Mayo Clinic Proceedings, vol. 79, no. 8, pp. 1036–1046, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Kasasbeh, D. S. Chi, and G. Krishnaswamy, “Inflammatory aspects of sleep apnea and their cardiovascular consequences,” Southern Medical Journal, vol. 99, no. 1, pp. 58–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Hartmann, M. Tschöp, R. Fischer et al., “High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein,” Cytokine, vol. 12, no. 3, pp. 246–252, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. A. N. Vgontzas, D. A. Papanicolaou, E. O. Bixler et al., “Circadian interleukin-6 secretion and quantity and depth of sleep,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 8, pp. 2603–2607, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. A. N. Vgontzas, D. A. Papanicolaou, E. O. Bixler, A. Kales, K. Tyson, and G. P. Chrousos, “Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 5, pp. 1313–1316, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. A. S. M. Shamsuzzaman, M. Winnicki, P. Lanfranchi et al., “Elevated C-reactive protein in patients with obstructive sleep apnea,” Circulation, vol. 105, no. 21, pp. 2462–2464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. S. K. Venugopal, S. Devaraj, I. Yuhanna, P. Shaul, and I. Jialal, “Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells,” Circulation, vol. 106, no. 12, pp. 1439–1441, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. K. J. Woollard, D. C. Phillips, and H. R. Griffiths, “Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells,” Clinical & Experimental Immunology, vol. 130, no. 2, pp. 256–262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Galiè, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT),” European Heart Journal, vol. 30, no. 20, pp. 2493–2537, 2009. View at Publisher · View at Google Scholar
  50. M. Rabinovitch, “Molecular pathogenesis of pulmonary arterial hypertension,” The Journal of Clinical Investigation, vol. 122, no. 12, pp. 4306–4313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Y. Chan and J. Loscalzo, “Pathogenic mechanisms of pulmonary arterial hypertension,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 1, pp. 14–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Humbert, N. W. Morrell, S. L. Archer et al., “Cellular and molecular pathobiology of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 43, no. 12, pp. 13S–24S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. J. Thorley, P. A. Ford, M. A. Giembycz, P. Goldstraw, A. Young, and T. D. Tetley, “Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages,” The Journal of Immunology, vol. 178, no. 1, pp. 463–473, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Fartoukh, D. Emilie, C. Le Gall, G. Monti, G. Simonneau, and M. Humbert, “Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension,” Chest, vol. 114, no. 1, pp. 50S–51S, 1998. View at Google Scholar · View at Scopus
  55. M. Humbert, G. Monti, F. Brenot et al., “Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 5, pp. 1628–1631, 1995. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Rondelet, C. Dewachter, F. Kerbaul et al., “Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure,” European Heart Journal, vol. 33, no. 8, pp. 1017–1026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. M. I. Suwara, N. J. Green, L. A. Borthwick et al., “IL-1a released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts,” Mucosal Immunology, vol. 7, no. 3, pp. 684–693, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. Z. Zeng, Y. Li, Z. Jiang, C. Wang, B. Li, and W. Jiang, “The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling,” Cardiovascular Therapeutics, vol. 28, no. 1, pp. 23–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Li, L. Yang, J. Shen, C. Wang, and Z. Jiang, “The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation,” Anesthesia & Analgesia, vol. 105, no. 4, pp. 1034–1041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Lu, H. Shimpo, A. Shimamoto et al., “Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats,” Journal of Thoracic and Cardiovascular Surgery, vol. 128, no. 6, pp. 850–859, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. H. J. Mortimer, A. J. Peacock, A. Kirk, and D. J. Welsh, “p38 MAP kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation,” Pulmonary Pharmacology and Therapeutics, vol. 20, no. 6, pp. 718–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. P. A. Baeuerle and T. Henkel, “Function and activation of NF-κB in the immune system,” Annual Review of Immunology, vol. 12, pp. 141–179, 1994. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Thanos and T. Maniatis, “NF-kappaB: a lesson in family values,” Cell, vol. 80, no. 4, pp. 529–532, 1995. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Ghosh and M. Karin, “Missing pieces in the NF-κB puzzle,” Cell, vol. 109, no. 2, supplement, pp. S81–S96, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Lepetit, S. Eddahibi, E. Fadel et al., “Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension,” European Respiratory Journal, vol. 25, no. 5, pp. 834–842, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Rossi, C. Zappa, A. Ferraresi, and V. Santiemma, “Adrenomedullin inhibits angiotensin II-induced contraction in human aortic smooth muscle cells,” Regulatory Peptides, vol. 133, no. 1–3, pp. 155–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. T.-J. Kim and Y.-P. Yun, “Antiproliferative activity of NQ304, a synthetic 1,4-naphthoquinone, is mediated via the suppressions of the PI3K/Akt and ERK1/2 signaling pathways in PDGF-BB-stimulated vascular smooth muscle cells,” Vascular Pharmacology, vol. 46, no. 1, pp. 43–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Fan, C. Li, C. Qin et al., “Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells,” DNA and Cell Biology, vol. 33, no. 1, pp. 12–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Miura and M. Tanno, “Mitochondria and GSK-3β in cardioprotection against ischemia/reperfusion injury,” Cardiovascular Drugs and Therapy, vol. 24, no. 3, pp. 255–263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Castria, R. M. Refini, E. Bargagli, F. Mezzasalma, C. Pierli, and P. Rottoli, “Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress,” International Journal of Immunopathology and Pharmacology, vol. 25, no. 3, pp. 681–689, 2012. View at Google Scholar · View at Scopus
  71. J. S. Smith, D. Gorbett, J. Mueller, R. Perez, and C. J. Daniels, “Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo,” The American Journal of the Medical Sciences, vol. 346, no. 3, pp. 221–225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Laks, B. Lehrhaft, R. R. Grunstein, and C. E. Sullivan, “Pulmonary hypertension in obstructive sleep apnoea,” European Respiratory Journal, vol. 8, no. 4, pp. 537–541, 1995. View at Google Scholar · View at Scopus
  73. R. Kessler, A. Chaouat, E. Weitzenblum et al., “Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences,” European Respiratory Journal, vol. 9, no. 4, pp. 787–794, 1996. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Belaidi, M. Joyeux-Faure, C. Ribuot, S. H. Launois, P. Levy, and D. Godin-Ribuot, “Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea,” Journal of the American College of Cardiology, vol. 53, no. 15, pp. 1309–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Held, J. Walthelm, S. Baron, C. Roth, and B. Jany, “Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation,” European Respiratory Journal, vol. 43, no. 1, pp. 156–165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Mokhlesi and A. Tulaimat, “Recent advances in obesity hypoventilation syndrome,” Chest, vol. 132, no. 4, pp. 1322–1336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. C. T. Taylor and J. C. McElwain, “Ancient atmospheres and the evolution of oxygen sensing via the hypoxia-inducible factor in metazoans,” Physiology, vol. 25, no. 5, pp. 272–279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. G. L. Semenza and G. L. Wang, “A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation,” Molecular and Cellular Biology, vol. 12, no. 12, pp. 5447–5454, 1992. View at Google Scholar · View at Scopus
  79. G. L. Wang, B.-H. Jiang, E. A. Rue, and G. L. Semenza, “Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 12, pp. 5510–5514, 1995. View at Publisher · View at Google Scholar · View at Scopus
  80. C. T. Taylor, “Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation,” Journal of Physiology, vol. 586, no. 17, pp. 4055–4059, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. C. J. Schofield and P. J. Ratcliffe, “Oxygen sensing by HIF hydroxylases,” Nature Reviews Molecular Cell Biology, vol. 5, no. 5, pp. 343–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. G. L. Semenza, “Hypoxia-inducible factors in physiology and medicine,” Cell, vol. 148, no. 3, pp. 399–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. G. L. Semenza, “Mechanisms of disease: oxygen sensing, homeostasis, and disease,” The New England Journal of Medicine, vol. 365, no. 6, pp. 537–547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. H. K. Eltzschig and T. Eckle, “Ischemia and reperfusion—from mechanism to translation,” Nature Medicine, vol. 17, no. 11, pp. 1391–1401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. H. K. Eltzschig, M. V. Sitkovsky, and S. C. Robson, “Purinergic signaling during inflammation,” The New England Journal of Medicine, vol. 367, no. 24, pp. 2322–2333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. H. K. Eltzschig and P. Carmeliet, “Hypoxia and inflammation,” The New England Journal of Medicine, vol. 364, no. 7, pp. 656–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. H. K. Eltzschig, D. L. Bratton, and S. P. Colgan, “Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases,” Nature Reviews Drug Discovery, vol. 13, no. 11, pp. 852–869, 2014. View at Publisher · View at Google Scholar
  88. W. G. Kaelin Jr. and P. J. Ratcliffe, “Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway,” Molecular Cell, vol. 30, no. 4, pp. 393–402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. G. L. Semenza, “Regulation of oxygen homeostasis by hypoxia-inducible factor 1,” Physiology, vol. 24, no. 2, pp. 97–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. P. H. Maxwell, M. S. Wlesener, G.-W. Chang et al., “The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis,” Nature, vol. 399, no. 6733, pp. 271–275, 1999. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Ema, S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda, and Y. Fujii-Kuriyama, “A novel bHLH-PAS factor with close sequence similarity to hypoxia- inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4273–4278, 1997. View at Publisher · View at Google Scholar · View at Scopus
  92. Y.-Z. Gu, S. M. Moran, J. B. Hogenesch, L. Wartman, and C. A. Bradfield, “Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α,” Gene Expression, vol. 7, no. 3, pp. 205–213, 1998. View at Google Scholar · View at Scopus
  93. Y. Makino, A. Kanopka, W. J. Wilson, H. Tanaka, and L. Poellinger, “Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus,” Journal of Biological Chemistry, vol. 277, no. 36, pp. 32405–32408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Makino, R. Cao, K. Svensson et al., “Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression,” Nature, vol. 414, no. 6863, pp. 550–554, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. S. P. Colgan and C. T. Taylor, “Hypoxia: an alarm signal during intestinal inflammation,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 5, pp. 281–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Peyssonnaux, P. Cejudo-Martin, A. Doedens, A. S. Zinkernagel, R. S. Johnson, and V. Nizet, “Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis,” Journal of Immunology, vol. 178, no. 12, pp. 7516–7519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Kuhlicke, J. S. Frick, J. C. Morote-Garcia, P. Rosenberger, and H. K. Eltzschig, “Hypoxia inducible factor (HIF)-1 coordinates induction of toll-like receptors TLR2 and TLR6 during hypoxia,” PLoS ONE, vol. 2, no. 12, Article ID e1364, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. G. M. Tannahill, A. M. Curtis, J. Adamik et al., “Succinate is an inflammatory signal that induces IL-1β through HIF-1α,” Nature, vol. 496, no. 7444, pp. 238–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. M. A. Schmit, V. Mirakaj, M. Stangassinger, K. König, D. Köhler, and P. Rosenberger, “Vasodilator phosphostimulated protein (VASP) protects endothelial barrier function during hypoxia,” Inflammation, vol. 35, no. 2, pp. 566–573, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. E. L. Campbell, W. J. Bruyninckx, C. J. Kelly et al., “Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation,” Immunity, vol. 40, no. 1, pp. 66–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. C. C. Scholz, M. A. S. Cavadas, M. M. Tambuwala et al., “Regulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 46, pp. 18490–18495, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Bartels, A. Grenz, and H. K. Eltzschig, “Hypoxia and inflammation are two sides of the same coin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 46, pp. 18351–18352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. X. Teng, D. Li, H. C. Champion, and R. A. Johns, “FIZZ1/RELMα, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties,” Circulation Research, vol. 92, no. 10, pp. 1065–1067, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. D. J. Angelini, Q. Su, K. Yamaji-Kegan et al., “Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) induces the vascular and hemodynamic changes of pulmonary hypertension,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 296, no. 4, pp. L582–L593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Liu, S. M. Dhanasekaran, H. Jin et al., “FIZZ1 stimulation of myofibroblast differentiation,” The American Journal of Pathology, vol. 164, no. 4, pp. 1315–1326, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. C. Doucet, D. Brouty-Boyé, C. Pottin-Clémenceau, G. W. Canonica, C. Jasmin, and B. Azzarone, “Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma,” The Journal of Clinical Investigation, vol. 101, no. 10, pp. 2129–2139, 1998. View at Publisher · View at Google Scholar · View at Scopus
  107. F. Huaux, T. Liu, B. McGarry, M. Ullenbruch, and S. H. Phan, “Dual roles of IL-4 in lung injury and fibrosis,” Journal of Immunology, vol. 170, no. 4, pp. 2083–2092, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. T. E. King Jr., A. Pardo, and M. Selman, “Idiopathic pulmonary fibrosis,” The Lancet, vol. 378, no. 9807, pp. 1949–1961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. N. I. Chaudhary, G. J. Roth, F. Hilberg et al., “Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis,” European Respiratory Journal, vol. 29, no. 5, pp. 976–985, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. W. R. Coward, G. Saini, and G. Jenkins, “The pathogenesis of idiopathic pulmonary fibrosis,” Therapeutic Advances in Respiratory Disease, vol. 4, no. 6, pp. 367–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. T. A. Wynn, “Integrating mechanisms of pulmonary fibrosis,” Journal of Experimental Medicine, vol. 208, no. 7, pp. 1339–1350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. P. F. Piguet, C. Ribaux, V. Karpuz, G. E. Grau, and Y. Kapanci, “Expression and localization of tumor necrosis factor-α and its mRNA in idiopathic pulmonary fibrosis,” The American Journal of Pathology, vol. 143, no. 3, pp. 651–655, 1993. View at Google Scholar · View at Scopus
  113. Y. Miyazaki, K. Araki, C. Vesin et al., “Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis,” The Journal of Clinical Investigation, vol. 96, pp. 250–259, 1995. View at Google Scholar
  114. M. Hasegawa, M. Fujimoto, K. Kikuchi, and K. Takehara, “Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis,” Journal of Rheumatology, vol. 24, no. 4, pp. 663–665, 1997. View at Google Scholar · View at Scopus
  115. C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. P. L. Simonian, C. L. Roark, F. Wehrmann et al., “Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis,” Journal of Immunology, vol. 182, no. 1, pp. 657–665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. M. S. Wilson, S. K. Madala, T. R. Ramalingam et al., “Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent,” The Journal of Experimental Medicine, vol. 207, no. 3, pp. 535–552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Yamaji-Kegan, E. Takimoto, A. Zhang et al., “Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 306, no. 12, pp. L1090–L1103, 2014. View at Google Scholar
  120. V. Balasubramaniam, T. D. Le Cras, D. D. Ivy, T. R. Grover, J. P. Kinsella, and S. H. Abman, “Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 284, no. 5, pp. L826–L833, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. D. M. Mosser and J. P. Edwards, “Exploring the full spectrum of macrophage activation,” Nature Reviews Immunology, vol. 8, no. 12, pp. 958–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Vergadi, M. S. Chang, C. Lee et al., “Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension,” Circulation, vol. 123, no. 18, pp. 1986–1995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. E. Naik and V. M. Dixit, “Mitochondrial reactive oxygen species drive proinflammatory cytokine production,” The Journal of Experimental Medicine, vol. 208, no. 3, pp. 417–420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, “A role for mitochondria in NLRP3 inflammasome activation,” Nature, vol. 469, pp. 221–225, 2011. View at Google Scholar
  125. S. L. Cassel, S. C. Eisenbarth, S. S. Iyer et al., “The Nalp3 inflammasome is essential for the development of silicosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9035–9040, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. C. Dostert, V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp, “Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica,” Science, vol. 320, no. 5876, pp. 674–677, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. F. Huaux, T. Liu, B. McGarry, M. Ullenbruch, Z. Xing, and S. H. Phan, “Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis,” Journal of Immunology, vol. 171, no. 10, pp. 5470–5481, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Y. Cho, M. Miller, K. J. Baek et al., “Inhibition of airway remodeling in IL-5-deficient mice,” The Journal of Clinical Investigation, vol. 113, no. 4, pp. 551–560, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. P. C. Fulkerson, C. A. Fischetti, and M. E. Rothenberg, “Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling,” The American Journal of Pathology, vol. 169, no. 6, pp. 2117–2126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. R. M. Reiman, R. W. Thompson, C. G. Feng et al., “Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity,” Infection and Immunity, vol. 74, no. 3, pp. 1471–1479, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. E. Hams, M. E. Armstrong, J. L. Barlow et al., “IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 1, pp. 367–372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  132. H. H. Walford and T. A. Doherty, “STAT6 and lung inflammation,” JAK-STAT, vol. 2, no. 4, Article ID e25301, 2014. View at Publisher · View at Google Scholar
  133. T. Doherty and D. Broide, “Cytokines and growth factors in airway remodeling in asthma,” Current Opinion in Immunology, vol. 19, no. 6, pp. 676–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Fichtner-Feigl, W. Strober, K. Kawakami, R. K. Puri, and A. Kitani, “IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis,” Nature Medicine, vol. 12, no. 1, pp. 99–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. P. C. Fulkerson, C. A. Fischetti, L. M. Hassman, N. M. Nikolaidis, and M. E. Rothenberg, “Persistent effects induced by IL-13 in the lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 3, pp. 337–346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. J. J. Cardasis, H. MacMahon, and A. N. Husain, “The spectrum of lung disease due to chronic occult aspiration,” Annals of the American Thoracic Society, vol. 11, no. 6, pp. 865–873, 2014. View at Publisher · View at Google Scholar
  137. A. S. Lee, I. Mira-Avendano, J. H. Ryu, and C. E. Daniels, “The burden of idiopathic pulmonary fibrosis: an unmet public health need,” Respiratory Medicine, vol. 108, pp. 955–967, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. N. Hosogai, A. Fukuhara, K. Oshima et al., “Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation,” Diabetes, vol. 56, no. 4, pp. 901–911, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. J. Ye, “Emerging role of adipose tissue hypoxia in obesity and insulin resistance,” International Journal of Obesity, vol. 33, no. 1, pp. 54–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. J. Yin, Z. Gao, Q. He, D. Zhou, Z. Guo, and J. Ye, “Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue,” American Journal of Physiology: Endocrinology and Metabolism, vol. 296, no. 2, pp. E333–E342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Pasarica, O. R. Sereda, L. M. Redman et al., “Reduced adipose tissue oxygenation in human obesity evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response,” Diabetes, vol. 58, no. 3, pp. 718–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. M. E. Rausch, S. Weisberg, P. Vardhana, and D. V. Tortoriello, “Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration,” International Journal of Obesity, vol. 32, no. 3, pp. 451–463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. J. Ye, Z. Gao, J. Yin, and Q. He, “Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 293, no. 4, pp. E1118–E1128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. N. Halberg, T. Khan, M. E. Trujillo et al., “Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue,” Molecular and Cellular Biology, vol. 29, no. 16, pp. 4467–4483, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. K. Sun, C. M. Kusminski, and P. E. Scherer, “Adipose tissue remodeling and obesity,” The Journal of Clinical Investigation, vol. 121, no. 6, pp. 2094–2101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. T. Khan, E. S. Muise, P. Iyengar et al., “Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI,” Molecular and Cellular Biology, vol. 29, no. 6, pp. 1575–1591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. R. W. Tobin, C. E. Pope II, C. A. Pellegrini, M. J. Emond, J. Sillery, and G. Raghu, “Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis,” The American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 6, pp. 1804–1808, 1998. View at Publisher · View at Google Scholar · View at Scopus
  148. H. Yasuhara, Y. Miyake, T. Toyokawa et al., “Large waist circumference is a risk factor for reflux esophagitis in Japanese males,” Digestion, vol. 81, no. 3, pp. 181–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. J. L. Colombo and T. K. Hallberg, “Airway reactivity following repeated milk aspiration in rabbits,” Pediatric Pulmonology, vol. 29, no. 2, pp. 113–119, 2000. View at Publisher · View at Google Scholar
  150. F. D. T. Q. S. Lopes, G. S. Alvarenga, R. Quiles et al., “Pulmonary responses to tracheal or esophageal acidification in guinea pigs with airway inflammation,” Journal of Applied Physiology, vol. 93, no. 3, pp. 842–847, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. D. N. Tuchman, J. T. Boyle, A. I. Pack et al., “Comparison of airway responses following tracheal or esophageal acidification in the cat,” Gastroenterology, vol. 87, no. 4, pp. 872–881, 1984. View at Google Scholar · View at Scopus
  152. R. K. Coker and G. J. Laurent, “Pulmonary fibrosis: cytokines in the balance,” European Respiratory Journal, vol. 11, no. 6, pp. 1218–1221, 1998. View at Publisher · View at Google Scholar · View at Scopus
  153. P. L. Molyneaux, M. J. Cox, S. A. Willis-Owen et al., “The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 8, pp. 906–913, 2014. View at Publisher · View at Google Scholar
  154. W. H. Ibrahim, “Helicobacter pylori eradication in the management of idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 30, no. 2, pp. 395–396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. L. Richeldi, H. R. Davies, G. Ferrara, and F. Franco, “Corticosteroids for idiopathic pulmonary fibrosis,” The Cochrane Database of Systematic Reviews, no. 3, Article ID CD002880, 2003. View at Publisher · View at Google Scholar
  156. H. R. Davies, L. Richeldi, and E. H. Walters, “Immunomodulatory agents for idiopathic pulmonary fibrosis,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD003134, 2003. View at Google Scholar · View at Scopus
  157. N. W. Todd, I. G. Luzina, and S. P. Atamas, “Molecular and cellular mechanisms of pulmonary fibrosis,” Fibrogenesis and Tissue Repair, vol. 5, article 11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. M. S. Wilson and T. A. Wynn, “Pulmonary fibrosis: pathogenesis, etiology and regulation,” Mucosal Immunology, vol. 2, no. 2, pp. 103–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. P. J. Barnes and I. M. Adcock, “Glucocorticoid resistance in inflammatory diseases,” The Lancet, vol. 373, no. 9678, pp. 1905–1917, 2009. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Watanabe, N. Nitta, A. Sonoda et al., “Inhibition of fibrosis and inflammation by triple therapy with pirfenidone, edaravone and erythropoietin in rabbits with drug-induced lung injury: comparison of CT imaging and pathological findings,” Experimental and Therapeutic Medicine, vol. 6, no. 5, pp. 1096–1100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. E. Conte, E. Gili, E. Fagone, M. Fruciano, M. Iemmolo, and C. Vancheri, “Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts,” European Journal of Pharmaceutical Sciences, vol. 58, no. 1, pp. 13–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  162. D. Szukiewicz, J. Kochanowski, T. K. Mittal, M. Pyzlak, G. Szewczyk, and K. Cendrowski, “CX3CL1 (fractalkine) and TNFα production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling,” Inflammation Research, vol. 63, no. 3, pp. 179–189, 2014. View at Publisher · View at Google Scholar · View at Scopus
  163. A. Bast, A. R. Weseler, G. R. M. M. Haenen, and G. J. M. den Hartog, “Oxidative stress and antioxidants in interstitial lung disease,” Current Opinion in Pulmonary Medicine, vol. 16, no. 5, pp. 516–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. L. Hecker, R. Vittal, T. Jones et al., “NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury,” Nature Medicine, vol. 15, no. 9, pp. 1077–1081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. A. Salazar-Montes, L. Ruiz-Corro, A. López-Reyes, E. Castrejón-Gómez, and J. Armendáriz-Borunda, “Potent antioxidant role of pirfenidone in experimental cirrhosis,” European Journal of Pharmacology, vol. 595, no. 1–3, pp. 69–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  166. Y. Mitani, K. Sato, Y. Muramoto et al., “Superoxide scavenging activity of pirfenidone-iron complex,” Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 19–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. B. K. Cenik, K. T. Ostapoff, D. E. Gerber, and R. A. Brekken, “BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer,” Molecular Cancer Therapeutics, vol. 12, no. 6, pp. 992–1001, 2013. View at Publisher · View at Google Scholar · View at Scopus
  168. P. Steiropoulos, “Can we predict the survival of idiopathic pulmonary fibrosis patients? Sleep must be re-appreciated,” Journal of Clinical Sleep Medicine, vol. 9, no. 6, pp. 603–604, 2013. View at Publisher · View at Google Scholar · View at Scopus